The Organ Donor Problem: Redefining a Medical Crisis into a Solvable Engineering Problem

Aditya Chaudhry

23 July 2025

Abstract

The global organ donor shortage represents one of the most persistent and devastating medical crises of our time. Despite decades of policy reform and public health campaigns, the demand for transplantable organs vastly exceeds supply, leaving millions without access to life-saving treatment. Conventional approaches frame the organ donor problem as primarily medical and ethical, which has limited the scope of practical solutions.

This white paper presents a reframing: treating the organ donor shortage as a solvable engineering problem. We introduce an outline ecosystem that integrates three technological domains: **medical devices** for advanced preservation and monitoring of donor organs, **surgical robotics** to enhance precision and efficiency in transplantation procedures, and **artificial organs and bioengineered systems** to augment or replace biological supply.

By conceptualizing these domains as interconnected components of a systemic solution, we argue that the crisis can shift from scarcity-driven limitations toward engineered scalability. This paradigm aims not only to expand the availability of viable organs but also to redefine transplantation as a sustainable, technology-enabled continuum of care.

1 Introduction

Organ transplantation has saved countless lives, yet thousands die each year while waiting for suitable organs. The prevailing discourse emphasizes ethics, clinical constraints, and culture, but often underweights opportunities for structural intervention at the levels of technology, process, and systems. We argue that reframing the organ donor shortage as an engineering problem enables practical, scalable solutions that complement medical advances. Specifically, we motivate a technology stack spanning directed tissue engineering

[1], organ-on-a-chip and microphysiological systems [2], nanotechnology-enabled artificial organs [3], and procedure-enabling surgical robotics with explicit human-factors design [4]. Quantitatively, the stakes are high: individuals are multiple times more likely to need a transplant than to become a donor [5], and each additional deceased donor yields tens of life-years saved across recipients [6]. These realities motivate a systems-engineering approach to preservation, logistics, allocation, and operative delivery.

2 The Organ Donor Problem

Organ transplantation remains constrained by a structural imbalance: the number of patients who need organs persistently exceeds the number of transplantable organs available. This shortage drives excess mortality on waiting lists, fuels illicit markets, and is compounded by narrow time windows for organ viability.

2.1 Persistent Scarcity: Demand Exceeds Supply

Across lifetimes, individuals are *five to six times more likely* to need an organ transplant than to become a deceased organ donor, a mismatch that translates into prolonged waits and preventable deaths on waiting lists [5, 7]. Quantitatively, each additional deceased donor can yield *approximately 31–56 life-years* saved across multiple recipients, underscoring the public-health magnitude of the shortfall [6].

2.2 Crimes and Exploitation

Chronic scarcity creates incentives for illicit procurement and exploitation. Recent global assessments document trafficking for organ removal within broader human-trafficking networks, with organized groups leveraging cross-border routes and vulnerable populations—eroding safety, equity, and public trust in legitimate donation systems [8].

2.3 Different Lifespans of Organs

Allocation and logistics are further complicated by organ-specific preservation limits. Livers, hearts, and lungs tolerate only short periods of cold ischemia, while kidneys allow comparatively longer storage; prolonged ischemia is independently associated with delayed graft function and worse outcomes [9, 10]. Engineering advances are extending these windows: donor hearts after circulatory death, reanimated on normothermic perfusion, show non-inferior 6-month survival compared to standard brain-death donors [11], and portable ex vivo lung perfusion enables extended assessment and safe prolongation of preservation while increasing utilization [12]. These technologies illustrate how engineering can mitigate time-to-failure constraints that otherwise lead to organ wastage despite need [9].

3 Solution: An Engineered Ecosystem Beyond Donor Scarcity

3.1 Goal

Develop a technology ecosystem that progressively reduces dependence on donor availability by (i) expanding, stabilizing, and instrumenting organ supply with advanced **medical devices**, (ii) deploying **semi-autonomous surgical robotics** to deliver consistent, high-quality implantation, and (iii) enabling **designed, fabricated organs**—built with precision via electrospinning, directed self-assembly, and organ-on-a-chip workflows—to ultimately complement and, where feasible, replace reliance on biological donors [1, 2, 3].

3.2 System Architecture

1. **Medical Devices for Preservation, Assessment, and Logistics**
   Objective: Maximize organ uptime, quality, and geographic reach; create instrumentation and data needed for automation and QC.
   Capabilities:

   - *Normothermic / ex vivo perfusion* platforms to reanimate, assess, and transport organs (e.g., donor hearts after circulatory death with noninferior 6-month outcomes; portable EVLP to extend lung preservation and utilization) [11, 12].
   - *Organ-specific preservation optimization* to reduce ischemic injury and time pressure (e.g., CIT reduction and monitoring in liver; kidney preservation principles) [9, 10].
   - *Expansion to difficult organs* via intestinal normothermic perfusion research for highly ischemia-sensitive grafts, building device know-how toward full artificial alternatives [13].

   These devices provide the sensing, telemetry, and process-control spine for handling organs like engineered products with measurable quality attributes.

2. **Surgical Robotics with Semi-Autonomous Execution**
   Objective: Deliver reproducible implantation at scale with safety, efficiency, and human-in-the-loop oversight.
   Capabilities:

   - *Task-level autonomy* (e.g., camera control, knot-tying, suture-line tracking, atraumatic retraction) coupled with workflow guidance and checklists informed by human-factors data to reduce flow disruptions and variability [4].
   - *Closed-loop integration* with preservation devices (handover from perfusion to implant), intraoperative imaging, and instrument telemetry for quality assurance and data capture.

Semi-autonomous assistance focuses clinician attention on judgment and exception handling while robotics standardize precision tasks and documentation [4].

3. **Artificial Organs and Biofabrication Pipeline**
   Objective: Progressively deliver *designed and fabricated* organs that meet specification.
   Core methods:

   - *Directed self-assembly* and morphogenesis-inspired engineering to build complex tissue architectures bottom-up [1].
   - *Electrospinning* of nanofiber scaffolds for anisotropic, biomimetic extracellular matrices; pairing with microphysiological culture for maturation [2, 3].
   - *Organ-on-a-chip (OOAC)* systems to prototype, stress-test, and validate tissues with realistic mechanical, transport, and cellular interfaces before scale-up [2].
   - *Nanotechnology-enabled biomaterials* (e.g., POSS–PCU, conductive/antimicrobial nanocomposites) to enhance mechanical robustness, biocompatibility, and sensorization—with early clinical precedents in synthetic hollow-organ constructs [3].

   Validation loop: Fabricated constructs are iteratively tested on-chip (function, barrier integrity, electrophysiology), then moved to large-animal and first-in-human contexts using the preservation and robotics stack for controlled implantation and monitoring [2, 3].

3.3 Vision: Saving Lives and Reducing Crime Through Engineered Supply

By expanding viable organ-time, standardizing implantation, and maturing biofabrication of "designed and printed" organs, this ecosystem aims to **save more lives** and **undercut incentives for illicit markets**. Quantitatively, each additional transplant opportunity yields substantial life-years across recipients [6]; narrowing the demand–supply gap reduces wait-list mortality and pressure on vulnerable populations. Because trafficking for organ removal coexists within broader human-trafficking networks, alleviating scarcity and tightening regulated, technology-enabled pathways should reduce the market space exploited by organized crime [8]. In short, treating organs as engineered systems—with specifications, quality metrics, and controllable processes—supports a transition from scarcity-driven harm to a *designed, auditable, and equitable* supply that protects patients and communities [5, 8].

4 Conclusion

The organ donor shortage persists because of a structural mismatch between need and supply, the narrow viability windows of biological organs, and the criminal externalities that scarcity invites. Framing this as a systems engineering problem makes the path forward clearer. The solution is an integrated ecosystem: (i) preservation and assessment *medical devices* that extend organ uptime and quality [11, 12, 9], (ii) *semi-autonomous surgical robotics* to standardize precision steps and reduce intraoperative variability with human-factors design [4], and (iii) *artificial organ* pipelines that use directed self-assembly, electrospinning, organ-on-a-chip, and nanomaterials to design and validate implantable tissues [1, 2, 3].

Success is measurable. Each additional transplant opportunity delivers tens of life-years across recipients [6], while the lifetime probability gap—people being several times more likely to need a transplant than to become donors—can be narrowed by increasing viable organ-time today and enabling designed supply tomorrow [5]. By expanding regulated, auditable, technology-enabled pathways, this ecosystem can also reduce the demand pressure that fuels trafficking for organ removal within broader human-trafficking networks [8]. Throughout, ethical guardrails on consent, fairness, and professional responsibility remain essential to sustain public trust [7].

In short, treating organs as engineered systems—with specifications, quality metrics, and controllable processes—offers a practical route to save more lives now and to build a future where life-saving replacement is limited less by donor scarcity and more by our capacity to design, manufacture, and safely deliver transplant-grade organs at scale [11, 12, 1, 2].

References

[1] Victor D. Varner and Celeste M. Nelson. "Toward the Directed Self-Assembly of Engineered Tissues". In: *Annual Review of Chemical and Biomolecular Engineering* 5 (2014), pp. 507–526. DOI: 10.1146/annurev-chembioeng-060713-040016.

[2] Qirui Wu, Jinfeng Liu, Xiaohong Wang, Lingyan Feng, Jinbo Wu, Xiaoli Zhu, Weijia Wen, and Xiuqing Gong. "Organ-on-a-chip: recent breakthroughs and future prospects". In: *BioMedical Engineering OnLine* 19.9 (2020). DOI: 10.1186/s12938-020-0752-0.

[3] G. Z. Teoh, P. Klanrit, M. Kasimatis, and A. M. Seifalian. "Role of nanotechnology in development of artificial organs". In: *Minerva Medica* 106.1 (Feb. 2015), pp. 17–33.

[4] Ken Catchpole, Colby Perkins, Catherine Bresee, M. Jonathon Solnik, Benjamin Sherman, John Fritch, Bruno Gross, Samantha Jagannathan, Niv Hakami-Majd, Raymund Avenido, and Jennifer T. Anger. "Safety, efficiency and learning curves in robotic surgery: a human factors analysis". In: *Surgical Endoscopy and Other Interventional Techniques* (2015). DOI: 10.1007/s00464-015-4671-2.

[5] Sam D. Shemie, Lynne Hornby, Jennifer Chandler, Peter Nickerson, and Jacquelyn Burkell. "Lifetime Probabilities of Needing an Organ Transplant Versus Donating an Organ After Death". In: *American Journal of Transplantation* 11.10 (2011), pp. 2085–2092. DOI: 10.1111/j.1600-6143.2011.03675.x.

[6] Mark A. Schnitzler, James F. Whiting, Daniel C. Brennan, Krista L. Lentine, Niraj M. Desai, William Chapman, Kevin C. Abbott, and Zoltan Kalog. "The Life-Years Saved by a Deceased Organ Donor". In: *American Journal of Transplantation* 5.9 (2005), pp. 2289–2296. DOI: 10.1111/j.1600-6143.2005.01021.x.

[7] Jennifer Lewis and Dale Gardiner. "Ethical and legal issues associated with organ donation and transplantation". In: *Surgery* 41.9 (2023).

[8] United Nations Office on Drugs and Crime. *Global Report on Trafficking in Persons 2024*. © United Nations, 2024. Vienna: UNODC, 2024. URL: https://www.unodc.org/unodc/data-and-analysis/glotip.html.

[9] Manuela Cesaretti, Alessandro Izzo, Roberta Anna Pellegrino, Alessandro Galli, and Orestes Mavrothalassitis. "Cold ischemia time in liver transplantation: An overview". In: *World Journal of Hepatology* 16.6 (2024), pp. 883–890. DOI: 10.4254/wjh.v16.i6.883.

[10] EAU Guidelines Dissemination Committee. *Kidney storage solutions, donor kidney biopsies, and preservation: Guidelines highlights*. European Association of Urology guidelines slide deck. 2022.

[11] Jacob N. Schroder, Chetan B. Patel, Adam D. DeVore, Benjamin S. Bryner, Stephanie Casalinova, Ashish Shah, Joshua W. Smith, Andrew G. Fiedler, Maheen Daneshmand, Stephen Silvestry, Arnar Geirsson, Viljee Pretorius, David L. Joyce, J. Y. Um, Fardad Esmailian, Kazuhiro Takeda, Kevin Mudy, Yasuhiro Shudo, Christopher T. Salerno, Steven M. Pham, David J. Goldstein, John Philpott, Joel Dunning, Livius Lozonschi, Glenn S. Couper, Hari R. Mallidi, Marc M. Givertz, Duc T. Pham, Alan W. Shaffer, Michael Kai, Mohammad A. Quader, Tarek Absi, Tarek S. Attia, Basel Shukrallah, Brian C. Sun, Matthew Farr, Mandeep R. Mehra, Joshua C. Madsen, Craig A. Milano, David A. D'Alessandro, et al. "Transplantation Outcomes with Donor Hearts after Circulatory Death". In: *The New England Journal of Medicine* 388.23 (2023), pp. 2121–2131. DOI: 10.1056/NEJMoa2212438.

[12] Syed Peer, Gabriel Loor, and Ramiro Fernandez. “Evolving experience with portable ex vivo lung perfusion in lung transplantation: a review”. In: *Current Challenges in Thoracic Surgery* 7 (2025), p. 14. DOI: 10.21037/ccts-24-45.

[13] Joseph M. Ladowski and Debra L. Sudan. “Normothermic Preservation of the Intestinal Allograft”. In: *Gastroenterology Clinics of North America* 53.2 (June 2024), pp. 221–231. DOI: 10.1016/j.gtc.2024.01.006.